Substance / Medication

Xylometazoline

Overview

Active Ingredient
xylometazoline
RxNorm CUI
39841

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Analgesic Effect of Cocaine and Lidocaine/Xylometazoline in Healthy Volunteers Undergoing Awake Nasal Intubation: A Randomized Controlled Crossover Trial.
Larsen Mo Haslund, Rosenkrantz Oscar, Knudsen Rasmus Linnebjerg et al. · Acta Anaesthesiol Scand · 2025
PMID: 40346884RCTFull text (PMC)
Cocaine versus xylometazoline to prevent epistaxis after nasotracheal intubation: A randomized trial.
Larsen Mo H, Rosenkrantz Oscar, Creuzburg Andreas et al. · Acta Anaesthesiol Scand · 2024
PMID: 38925575RCT
Topical nasal xylometazoline for flexible bronchoscopy (VAIN): A randomized, double-blind, placebo-controlled trial.
Sryma P B, Mittal Saurabh, Tiwari Pawan et al. · Respir Investig · 2021
PMID: 33518471RCT
Xylometazoline pretreatment reduces nasotracheal intubation-related epistaxis in paediatric dental surgery.
El-Seify Z A, Khattab A M, Shaaban A A et al. · Br J Anaesth · 2010
PMID: 20682569RCT
Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis.
Barnes Martyn L, Biallosterski Bart T, Gray Robert D et al. · Rhinology · 2005
PMID: 16405274RCT
[Treatment of inflammatory diseases of the upper respiratory tract -- comparison of a homeopathic complex remedy with xylometazoline].
Ammerschläger Hermann, Klein Peter, Weiser Michael et al. · Forsch Komplementarmed Klass Naturheilkd · 2005
PMID: 15772459Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Xylometazoline (substance)
SNOMED CT
372841007
UMLS CUI
C0078643
RxNorm CUI
39841

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.